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April 2018 Letters to the Editor e57Instead, we compared the rates of response to LCBI
and salvage chemotherapy after immunotherapy
after dividing chemotherapy regimens into
pemetrexed/platinum, taxane based, gemcitabine
based, and others.
In conclusion, though it is a retrospective study
with a small number of subjects, we think that our
study was well conducted with reasonable methods
and provides clinical evidence for future prospective
trials that will investigate the improved clinical out-
comes of salvage therapy after immune checkpoint
inhibitors.
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2017;35(suppl 15):9084.Comments on Prognostic
Impact of Margin Distance
and Tumor Spread through
Air Spaces in Limited
Resection for Primary
Lung CancerTo the Editor:
We read with great interest the study by Masai et al.1
The authors mentioned that spread through air
spaces is associated with local recurrence with ahazard ratio (HR) of 12.24 (95% conﬁdence interval
[CI]: 2.61–57.37) and, moreover, lymph vessel invasion
is associated with distant recurrence (HR ¼ 8.36, 95%
CI: 1.67- 41.87).1 Although the results were very
interesting, some methodological issues should be
considered.
It argued that relatively large effect estimate
and imprecise CI may be obvious indicators of sparse
data bias.2–4 In other words, there are inadequate
data for combination of predictor and outcome levels.2
Here, we are concerned that the estimated HRs
(and 95% CIs) for spread through air spaces and
lymph vessel invasion may be biased because of sparse
data bias.
Another important reason for imprecise CI for
estimate coefﬁcients is presence of collinearity
among the studied predictors. As a general rule,
collinearity among the predictors will be checked
before regression analysis by using variance inﬂation
factors.5
The authors did not attempt to check the propor-
tional hazards assumption before Cox regression anal-
ysis. As shown in the Figure 1 of Masai et al,1 it may
be that the proportional hazards assumption is violated
e58 Letters to the Editor Journal of Thoracic Oncology Vol. 13 No. 4for relapse-free survival curves for local recurrence of
patients undergoing limited resection according to the
studied variables.
Finally, it seems that there is degree of referral bias in
the estimated associations on account of selection of
patients referred to the National Cancer Center Hospital
for the study.
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2008.Response to Letter to the
Editor Titled “Comments
on Prognostic Impact of
Margin Distance and Tumor
Spread through Air Spaces
in Limited Resection for
Primary Lung Cancer”In Response:
We would like to thank Mansori et al.1 for their
interesting and thoughtful comments on our article
“Prognostic Impact of Margin Distance and Tumor
Spread through Air Spaces in Limited Resection for
Primary Lung Cancer.”2As they pointed out, the small number of cases of
disease recurrence and death in our study may have
resulted in imprecise conﬁdence intervals (CIs), which
may have slightly diminished the reliability of the iden-
tiﬁed indicators of poor prognosis. We are aware of
these limitations and have addressed them in the “Dis-
cussion” section of our article.2 We also think it
meaningful that two factors—the presence of tumor
spread through air spaces (STAS) and a short surgical
clearance distance (<1 cm)—were statistically
signiﬁcant as poor prognostic factors despite the small
numbers of recurrences and deaths in our study
cohort. It is likely that this small number of events is
the main cause of the imprecise CIs.
To calculate variance inﬂation factors (VIFs), we
reexamined our sample data by using SPSS software
(IBM Corp., Armonk, NY). For the four local recurrence
factors that were signiﬁcant in univariate analysis—
tumor margin, STAS, age, and tumor grade—the VIFs
were 1.011, 1.198, 1.071, and 1.249, respectively. The
VIFs for locoregional recurrence factors were 1.237 for
STAS; 1.621 for tumor grade; 1.072 for tumor size; and
1.461, 1.553, and 1.780 for lymph vessel, vascular, and
pleural invasion, respectively. Finally, for distant
recurrence factors, the VIFs were 1.231 for STAS, 1.076
for age; 1.635 for tumor grade; and 1.540, 1.786, and
1.455 for lymph vessel, vascular, and pleural invasion,
